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Identification and quantitation of candidate biomarker proteins in large numbers of individual tissues is required to validate specific
proteins, or panels of proteins, for clinical use as diagnostic, prognostic, toxicological, or therapeutic markers. Mass spectrometry (MS)
provides an exciting analytical methodology for this purpose. Liquid Tissue™ MS protein preparation allows researchers to utilize the vast,
already existing, collections of formalin-fixed paraffin-embedded (FFPE) tissues for the procurement of peptides and the analysis across a
variety of MS platforms.

INTRODUCTION

Proteomic profiling of diseased and normal tissue by mass
spectrometry (MS) is at an early stage, yet it promises to decipher
proteomic complexities of the tissue microenvironment and to
deliver biomarker information with appropriate pathologic and histologic relevance. Mass spectrometric profiling of the complex cellular
proteome obtained from diseased tissue has previously been
demonstrated with frozen cancer tissue (1–5). However, the use of
frozen tissue for such analysis is problematic for several reasons.
These difficulties include collecting sufficient tissue samples for large
studies (especially human tissue), the need to design the collection
of tissues in a prospective manner, the cumbersome nature of first
processing then analyzing frozen tissue, and the effort/expense of
storing such tissue on a long-term basis.
In contrast, formalin fixation of tissue is a routine process that
provides an easily stored archive of tissue that is pathologically
well-defined. Extensive archives of animal and human fixed tissue
have been collected, assembled, and stored at room temperature
for decades; the majority of which contain associated clinical and
experimental information representing an extremely valuable
untapped reservoir of potential biomarkers. However, current
methods of proteomic analysis for formalin-fixed tissue are limited
to immunohistochemistry (IHC) (6,7). This methodological limitation
is due to the protein cross-linking properties of formalin, which
preserves the proteins but renders them insoluble. This process
makes the proteins within these samples incompatible with many
of the discovery tools used in proteomics today, leaving these fixed
archival tissue collections inaccessible for further exploration of
biological knowledge (8–12).
Expression Pathology has developed a patent pending process,
termed Liquid Tissue™, for the extraction of peptides directly
from formalin-fixed tissue. This report demonstrates the analysis
of peptides obtained from formalin-fixed tissue utilizing the Liquid
Tissue process across a variety of MS platforms, including microcapillary reversed-phase liquid chromatography (μRPLC) tandem mass
spectrometry (MS/MS), matrix-assisted laser desorption ionization
(MALDI) tandem time-of-flight (TOF/TOF), and surface-enhanced
laser desorption ionization time-of-flight (SELDI-TOF). Results from
SELDI-TOF MS analysis reveal tissue-based patterns of protein
expression on a variety of chromatographic chip surfaces, while
multiple protein identifications were obtained from μRPLC-MS/MS,
all from a single Liquid Tissue extract. These results demonstrate
that the Liquid Tissue methodology provides the ability to unlock the
proteome of the world’s vast reservoir of archived tissue for largescale discovery and validation of biomarkers to improve disease
diagnosis and therapy.
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MATERIALS AND METHODS
Chemicals and Reagents

Formic acid (HCOOH) and trifluoroacetic acid (TFA) were
purchased from Sigma (St. Louis, MO, USA). High-performance
liquid chromatography (HPLC)-grade acetonitrile (ACN; CH3CN)
was obtained from EMD Chemicals (Gibbstown, NJ, USA). All
buffers and reagents were used as supplied from the manufacturer
and prepared in double-distilled water using a NANOPure Diamond®
water system (Barnstead International, Dubuque, IA, USA). The
Liquid Tissue MS Protein Prep kit was from Expression Pathology
(Gaithersburg, MD, USA).

Tissue Processing and Peptide Extraction

A formalin-fixed paraffin-embedded (FFPE) colon cancer tissue
with well-defined adenocarcinoma was analyzed by standard histological methods in order to identify a cancerous region consisting
of at least 70% cancerous epithelium with little to no observable
lymphocytic infiltration. A 5 μm-thick section was cut, placed on a
glass slide, and stained with hematoxylin and eosin (H&E) for identification of the cancerous region. A 10 μm-thick section was placed
on a second slide for tissue dissection and peptide procurement.
Paraffin was removed by treatment in SubX organic solvent
(Surgipath Medical Industries, Richmond, IL, USA) twice for 5 min,
followed by tissue rehydration through multiple graded ethanol
solutions and distilled water. The cancerous region of interest was
identified microscopically using the H&E-stained region to locate
the cells for macrodissection with a sterile 30-gauge hypodermic
needle in the rehydrated tissue section. The collected sample,
approximately 120,000 cells, was placed into a 1.5-mL low-binding
microcentrifuge tube containing 40 μL Liquid Tissue buffer.
Peptides were extracted utilizing the Liquid Tissue MS Protein
Prep kit according to the manufacturer’s protocol. Briefly, the cellular
material, suspended in the Liquid Tissue buffer, was incubated at
95°C for 90 min, then cooled on ice for 3 min. Trypsin was added
(approximately 15–18 U) followed by incubation at 37°C overnight.
Dithiothreitol was added to a final concentration of 10 mM, and the
samples were heated for 5 min at 95°C. The Liquid Tissue digestate
was stored at -20°C until analysis.

Nanoflow RPLC-MS/MS Analysis

μRPLC-MS/MS was performed using an Agilent 1100 capillary
LC system (Agilent Technologies, Palo Alto, CA, USA) coupled
online to a linear ion trap (LIT) mass spectrometer (LTQ; Thermo
Electron, Waltham, MA, USA). Separations were performed using
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SELDI-TOF Analysis

In preparation for the SELDI-TOF analysis, 25 μL Liquid Tissue
colon cancer extract (corresponding to approximately 75,000 cells)
were lyophilized and resuspended in 10 μL binding/wash buffer
[phosphate-buffered saline (PBS), pH 7.4, containing 0.1% Triton®
X-100]. The sample was then applied sequentially to the different
SELDI surfaces in the following manner.
The immobilized metal affinity capture (IMAC3) ProteinChip®
Array (Ciphergen Biosystems, Palo Alto, CA, USA) was loaded
with copper (100 mM CuSO4), washed with HPLC-grade water, and
incubated with 50 mM sodium acetate, pH 4.0. Following a brief
HPLC-grade water wash, the array was then pre-equilibrated in
binding/wash buffer. Sample was applied to the array surface using
a ProteinChip Bioprocessor (Ciphergen Biosystems) and incubated
for 2 h at ambient temperature with gentle agitation. Sample was
aspirated from the array surface and stored at 4°C until further use.
The array was washed twice with binding/wash buffer, followed by
two final 5 mM Tris, pH 8.0, washes. The ProteinChip Bioprocessor
was subsequently removed, and the array was air-dried prior to
analysis.
The weak cation exchange (WCX2) ProteinChip Array was
pretreated with 10 mM HCL and washed with HPLC-grade water
followed by pre-equilibration in binding/wash buffer (50 mM sodium
acetate, pH 4.5, containing 0.1% Triton X-100). Sample obtained
from the IMAC3 ProteinChip Array surface was lyophilized and
resuspended in 10 μL WCX2 binding/wash buffer. Sample was
applied to the WCX2 array surface using a ProteinChip Bioprocessor
and incubated for 2 h at ambient temperature with gentle agitation.
Sample was aspirated from the array surface and stored at 4°C until
June 2005

further use. The array was washed twice with binding/wash buffer,
followed by two final HPLC-grade water washes. The ProteinChip
Bioprocessor was subsequently removed, and the array air-dried
prior to analysis.
The strong anion exchange (SAX2) ProteinChip Array was preequilibrated with SAX2 binding/wash buffer (50 mM Tris, pH 8.0,
containing 0.1% Triton X-100). Sample obtained from the WCX2
ProteinChip Array surface was lyophilized and resuspended in 10
μL SAX2 binding/wash buffer. Sample was applied to the SAX2
array surface using a ProteinChip Bioprocessor and incubated for
2 h at ambient temperature with gentle agitation. The array was
washed twice with binding/wash buffer, followed by two final 5 mM
Tris, pH 8.0, washes. The ProteinChip Bioprocessor was subsequently removed, and the array air-dried prior to analysis.
For the gold ProteinChip Array surface, 5 μL liquid tissue
colon cancer extract (approximately 15,000 cells) were lyophilized
and resuspended in 3 μL HPLC-grade water. One microliter of a
saturated sinapinic acid solution in 50% ACN, 0.5% TFA was mixed
with the sample and directly spotted onto the gold array surface.
A total of 1 μL of a saturated sinapinic acid solution in 50%
ACN, 0.5% TFA was added to each spot of the IMAC3, WCX2,
and SAX2 ProteinChip Arrays. Data acquisition settings were
dependent upon the ProteinChip array type used: laser intensities
of 215–220, detector sensitivities of 8–10, and a molecular mass
range 0–100,000 Da, with 130 averaged shots per spectrum. Data
were collected and analyzed using ProteinChip software version 3.2
(Ciphergen Biosystems).

MALDI-TOF/TOF Analysis

MALDI-TOF/TOF analysis was performed on a Voyager 4700
MALDI-TOF/TOF™ mass spectrometer (Applied Biosystems,
Foster City, CA, USA). Sample was co-crystallized with an equivalent amount of α-cyano-4-hydroxycinnamic acid in 50% ACN,
0.1% TFA, and spotted directly on a stainless steel MALDI target
plate. Data was collected at a laser frequency of 200 Hz, and the
collision energy for CID was 1 keV (air was used as collision gas).
Post-acquisition baseline correction and smoothing was carried out
using software provided with the instrument.
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75 μm inner diameter (i.d.) × 360 μm outer diameter (o.d.) × 10
cm long fused silica capillary columns (Polymicro Technologies,
Phoenix, AZ, USA) that were slurry packed in-house with 3 μm, 300
Å pore size C-18 silica-bonded stationary phase (Vydac, Hysperia,
CA, USA). An aliquot of the Liquid Tissue extract (corresponding
to approximately 6000 cells) was desalted using C-18 ZipTip™
microcolumns (Millipore, Billerica, MA, USA), lyophilized, and resuspended in a minimal amount of 0.1% TFA prior to μRPLC-MS/MS
analysis. Following sample injection, the column was washed for 20
min with 98% mobile phase A (0.1% formic acid in water) at a flow
rate of 0.5 μL/min. Peptides were eluted using a linear gradient of
2% mobile phase B (0.1% formic acid in ACN) to 42% solvent B in
40 min, then to 98% B in an additional 28 min, all at a constant flow
rate of 250 nL/min.
The LIT-MS was operated in data-dependent MS/MS mode,
in which each full MS scan was followed by five MS/MS scans,
respectively, where the five most abundant peptide molecular
ions were selected for collision-induced dissociation (CID) using a
normalized collision energy of 35%. Dynamic exclusion was utilized
to minimize redundant selection of peptides previously selected for
CID. The heated capillary temperature and electrospray voltage
were set at 160°C and 1.5 kV, respectively. Data were collected
over a broad mass-to-charge (m/z) precursor ion selection scan
range of 400–2000.
Tandem mass spectra were searched against the UniProt
human proteomic database (01-04-05 release) from the European
Bioinformatics Institute (www.ebi.ac.uk/integr8) using SEQUEST®
(Thermo Electron). For a fully tryptic peptide to be considered
legitimately identified, it had to achieve stringent charge state and
proteolytic cleavage-dependent cross correlation (Xcorr) scores
of 1.9 for [M+H]1+, 2.2 for [M+2H]2+, and 3.1 for [M+3H]3+, and a
minimum delta correlation (∆Cn) of 0.08. SEQUEST results were
further filtered using software developed in-house to determine
unique peptides and proteins.
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Figure 1. Microcapillary reversed-phase liquid chromatography tandem
mass spectrometry (µRPLC-MS/MS) analysis of proteins extracted from
formalin-fixed colon cancer tissue. The efficiency of extracting proteins
from formalin-fixed colon cancer tissue using the Liquid Tissue method is
exemplified by the complexity of the resultant MS base peak chromatogram.
Over 600 peptides were identified from this µRPLC-MS/MS analysis of
formalin-fixed paraffin-embedded (FFPE) colon cancer tissue. m/z, mass-tocharge ratio.
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Figure 2. Surface-enhanced laser desorption ionization time-of-flight mass
spectrometry (SELDI-TOF MS) analysis. An analysis of the Liquid Tissue
extract was performed using SELDI-TOF MS. Colon cancer tissue extract was
processed on the following ProteinChip surfaces (top panel): (A) immobilized metal affinity chromatography (IMAC3), (B) strong anion exchange
(SAX2), (C) weak cation exchange (WCX2), (D) Au Chip. In each case, the
sample was lyophilized and resuspended in the appropriate binding buffer
for each chip surface. The sample was processed on the IMAC3 ProteinChip
array first, followed by WCX2, and then SAX2. The bottom panel shows the
virtual gel representation of each SELDI-MS spectrum (labeled as in the top
panel). The Gold ProteinChip was processed separately using an aliquot of
the original sample. m/z, mass-to-charge ratio.

RESULTS AND DISCUSSION

Even though the complexity makes qualitative and quantitative
analysis of a cell’s proteome difficult at best, observations carried
out at the protein level are inherently attractive because of the cause
and effect relationship between protein expression and biological
function. Informative pathologic context and relevance makes tissuebased studies important for linking proteins directly to biological and
disease processes. Fresh frozen tissue is difficult to obtain in large
numbers, expensive to store, and difficult to process, whereas large
collections of well-defined FFPE tissue with clinical history (and
often patient outcome) are readily available. Unfortunately, effective
and routine analysis of proteins in formalin-fixed tissue has been
limited to IHC. This limitation is due to the chemical cross-linking
properties of the common fixative reagent formalin, preventing
standard protein preparation methodologies from extracting soluble
protein from fixed tissue. Samples processed using the Liquid
Tissue methodology allow for the proteomic analysis of formalinfixed tissue not previously attainable.
One analytical method that can be used in conjunction with Liquid
Tissue protein extraction is MS. Multidimensional LC separation
methods when combined with MS provide sufficient separation and
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resolution to resolve, detect, and identify multiple proteins simultaneously, while providing broad proteome coverage of a single Liquid
Tissue protein preparation. In addition, MS pattern determination
utilizing SELDI technology can be employed to develop proteomic
profiles characterizing individual Liquid Tissue protein preparations.
A colon cancer Liquid Tissue extract was prepared from a FFPE
tissue and analyzed on numerous MS platforms to demonstrate
both the practicality and versatility of this approach. Microcapillary
RPLC-MS/MS analysis of the peptides obtained from this colon
cancer tissue extract resulted in the detection of thousands of
species as shown by the base peak chromatogram provided in
Figure 1. A single injection of a diluted extract resulted in the actual
identification of 629 unique, fully tryptic peptides representing over
350 unique proteins. Interestingly, a 20-fold lower injection volume
yielded almost the same results: 501 unique fully tryptic peptides
corresponding to 289 unique proteins. In each case, nearly 40% of
the unique proteins were identified by two or more unique peptides.
Many of the proteins identified in this study by multiple unique
peptides have previously been shown to have differential expression
levels in a comparison of normal mucosa and colorectal cancer
tissue, including annexin V, α-tropomyosin, and triosephosphate
isomerase (13).
While individual protein identification is important for correlating
potential expression levels with defined histological states, the
ability to evaluate proteomic patterns in various samples also plays
a significant role in biomarker discovery. Although still in its infancy,
proteomic pattern diagnostics using SELDI-TOF MS holds great
promise as a diagnostic tool. This technique uses the principles of
retentate chromatography to selectively bind biological samples
to the ProteinChip Array surface. Nonspecifically bound peptides,
proteins, salts, and other interfering compounds are washed away.
The peptides/proteins retained on the array surface are then
analyzed by TOF-MS after applying matrix to the sample. This
technique has been successfully employed for the early detection
of numerous cancers, including ovarian (14), prostate (15), cervical
(16), and pancreatic (17) cancers. SELDI-TOF MS of the colon
cancer tissue extract revealed complex peptide spectra on a variety
of chromatographic surfaces (Figure 2). Spectra obtained on the
WCX2 and SAX2 array surfaces are even more interesting, since
sample limitation required application of the same tissue extract
consecutively on these surfaces. For example, after the sample
was applied to the IMAC3 chip, the solution of peptides that did not
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Figure 3. Matrix-assisted laser desorption ionization tandem time-offlight (MALDI-TOF/TOF) analysis of proteins extracted from formalinfixed paraffin-embedded (FFPE) colon cancer tissue. Peptides extracted
from formalin-fixed colon cancer tissue using the Liquid Tissue method
were analyzed using a Voyager 4700 high-resolution MALDI-TOF/TOF mass
spectrometer showing a large number of observable peptides, including wellresolved low-level signals (inset). m/z, mass-to-charge ratio.
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bind to this surface was collected, relyophilized, and then applied to
the WCX2 chip. Likewise, the solution of peptides that did not bind
to the WCX2 chip were collected, relyophilized, and applied to the
SAX2 chip. Even with the loss of peptides bound to the previous
ProteinChip array type, complex spectra from a single sample
applied on multiple chromatographic surfaces was still observed.
The gold ProteinChip surface was used to evaluate the global colon
cancer Liquid Tissue extract. This approach to proteomic pattern
analysis offers a convenient alternative when sample is severely
limited and is insufficient to apply fresh samples to each ProteinChip
array surface.
As expected, the proteomic profiles of the peptides extracted
from the colon cancer tissue extract were dependent on the
chromatographic surface (i.e., IMAC3, WCX2, and SAX2) used. The
complexity of the spectra, however, is quite high, showing that the
extraction of peptides from formalin-fixed tissue using Liquid Tissue
is quite efficient. As has been done primarily for plasma and serum
samples, these results show that proteomic profiles generated
from formalin-fixed tissues also have the potential to be coupled
with SELDI-TOF MS for the identification of biomarkers of specific
diseases. Studying formalin-fixed tissues has many advantages
over studying biofluids, in that retrospective samples are easily
obtained, and issues related to sample collection are not as critical.
There is an active area of research that is attempting to use
higher resolution MS platforms to obtain proteomic patterns. To
meet this demand, we investigated the capability of obtaining
proteomic profiles of peptides extracted from FFPE tissues using
a high-resolution MALDI-TOF spectrometer. Peptides extracted
from a FFPE colon cancer tissue using the Liquid Tissue method
were spotted onto a target plate, and the spectrum was acquired
using a Voyager 4700 high-resolution MALDI-TOF/TOF mass
spectrometer. The resulting spectrum revealed a large number of
observable peptides as shown in Figure 3. Expansion of a region
within this spectrum shows that a large number of highly resolved,
low-level signals are readily detectable using this direct MALDI
approach (Figure 3, inset). These results show the complexity and
flexibility of the Liquid Tissue methodology to allow proteome investigation of peptides extracted from FFPE tissue on a variety of mass
spectrometry platforms.
The development of methods to use state-of-the-art proteomic
discovery tools to analyze FFPE tissue provides an exciting new
opportunity to identify disease-specific biomarkers in pathologically defined samples. There are vast archives of formalin-fixed
tissues, human and animal, spanning every conceivable condition
(disease, time, treatment, and outcomes), allowing acquisition of the
necessary numbers of samples to carry out in-depth analyses on a
disease of interest.
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